德西塔与IL-33/ST2轴合作,修改瘤微环境,改善黑色素瘤中对PD-1阻塞的反应
Francesco Noto1, Jacopo Mancini1, Adriana Rosa Gambardella1
1Department of Oncology and Molecular Medicine, Istituto Superiore Di Sanità, Rome, Italy.
概括
将Decitabine (DAC) 与IL-33结合起来,可以通过招募免疫细胞和表观遗传调节基因表达来增强抗黑色素瘤免疫力. 这种组合疗法改善了对PD-1封锁的反应,为黑色素瘤治疗提供了一种新的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 介质素-33 (IL-33) 是一种涉及癌症的警示剂,通过免疫细胞刺激在黑色素瘤中具有已知的抗瘤作用.
- 甲基化抑制剂Decitabine (DAC) 可以重新激活被沉默的基因,从而有可能增强癌细胞的免疫识别能力.
研究的目的:
- 研究IL-33和DAC对黑色素瘤的联合治疗效果.
- 探索内源IL-33信号传递在DAC的治疗反应和瘤免疫相互作用中的作用.
主要方法:
- 利用多细胞球体,器官芯片技术,以及小鼠和人类黑色素瘤的体内模型.
- 使用ST2-缺乏 (ST2-/-) 的小鼠来评估IL-33受体ST2信号的必要性.
- 进行了基于微流体的竞争性迁移测试,以评估免疫细胞化学反应.
主要成果:
- 结合DAC和IL-33治疗显著降低了黑色素瘤瘤的生长和延长了体内生存时间,优于单一药物.
- 组合疗法有效地将免疫细胞 (T 细胞,乙氨基酸细胞) 招募到瘤部位,并上调PD-1,增强对PD-1 阻塞的反应.
- DAC治疗通过脱甲基化增加了黑色素瘤细胞中的IL-33表达,这种效应以及免疫细胞的招募依赖于IL-33/ST2信号传递.
结论:
- DAC与IL-33/ST2轴协同作用,通过招募免疫细胞和表观遗传调节基因表达来对抗黑色素瘤.
- 这种组合疗法重塑了瘤免疫微环境,克服了对PD-1抑制的抵抗力.
- 这些发现突出了通过表观遗传重编程和免疫调节来提高黑色素瘤治疗疗效的有希望的策略.
相关概念视频
01:27Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
01:15Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K